Justices Told Generic Drugs At Risk From Skinny Label Ruling
The generic drug industry urged the U.S. Supreme Court on Friday to undo a Federal Circuit decision upholding a $235 million patent judgment against Teva, saying it will drive up drug...To view the full article, register now.
Already a subscriber? Click here to view full article